Unity Biotechnology is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Co. focuses on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases. Co.'s ophthalmology program includes UBX1325, which is its main drug candidate for age-related diseases of the eye including diabetic macular edema, age-related macular degeneration and diabetic retinopathy. Co.'s neurology program includes UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain. The UBX YTD return is shown above.
The YTD Return on the UBX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether UBX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the UBX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|